AR081045A1 - Derivados de quinazolinediona como moduladores trpa1 - Google Patents
Derivados de quinazolinediona como moduladores trpa1Info
- Publication number
- AR081045A1 AR081045A1 ARP090102199A ARP090102199A AR081045A1 AR 081045 A1 AR081045 A1 AR 081045A1 AR P090102199 A ARP090102199 A AR P090102199A AR P090102199 A ARP090102199 A AR P090102199A AR 081045 A1 AR081045 A1 AR 081045A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- crxry
- alkyl
- nrxry
- Prior art date
Links
- 101000764872 Homo sapiens Transient receptor potential cation channel subfamily A member 1 Proteins 0.000 title 1
- 102100026186 Transient receptor potential cation channel subfamily A member 1 Human genes 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 10
- 239000001257 hydrogen Substances 0.000 abstract 10
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 125000003342 alkenyl group Chemical group 0.000 abstract 8
- 125000000304 alkynyl group Chemical group 0.000 abstract 8
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 8
- 150000002431 hydrogen Chemical group 0.000 abstract 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 8
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 7
- 125000000623 heterocyclic group Chemical group 0.000 abstract 7
- 229920006395 saturated elastomer Polymers 0.000 abstract 7
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 abstract 6
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 5
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 5
- 125000004429 atom Chemical group 0.000 abstract 4
- 125000004122 cyclic group Chemical group 0.000 abstract 4
- 125000005842 heteroatom Chemical group 0.000 abstract 4
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 230000001052 transient effect Effects 0.000 abstract 2
- -1 -NRxRy Chemical class 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 229910003813 NRa Inorganic materials 0.000 abstract 1
- 108060008646 TRPA Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente proporciona derivados quinazolinadiona como moduladores TRPA (Potenciales Receptores Transitorios subfamilia A). En particular, los compuestos para el tratamiento o prevencion de enfermedades, condiciones y/o desordenes modulados por TRPA1 (Potenciales Receptores Transitorios subfamilia A, miembro 1). También se proporcionan aquí composiciones farmacéuticas de los mismos, y métodos para tratar o prevenir enfermedades, condiciones y/o desordenes modulados por TRPA1. Reivindicacion 1: Un compuesto de la formula (1) o sus ésteres, tautomeros, estereoisomeros, o sus sales farmacéuticamente aceptables, donde, anillo A es aril, heteroaril, heterociclil o cicloalquil; en cada ocurrencia R1 y R2 es independientemente seleccionada de hidrogeno, hidroxilo, sustituido o no sustituido alquil, sustituido o no sustituido alquenil, sustituido o no sustituido alquinil, sustituido o no sustituido cicloalquil, sustituido o no sustituido cicloalquilalquil, (CRxRy)nORx, CORx, COORx, CONRxRy, SO2NRxRy, NRxRy, NRx(CRxRy)nORx, NRx(CRxRy)nCN, (CH2)nNRxRy, (CH2)nCHRxRy, (CRxRy)NRxRy, NRx(CRxRy)nCONRxRy, (CH2)nNHCORx y (CH2)nNH(CH2)nSO2Rx, y (CH2)nNHSO2Rx; cada ocurrencia de Rx y Ry es independientemente seleccionada de hidrogeno, hidroxilo, halogeno, sustituido o no sustituido alquil, sustituido o no sustituido alquenil, sustituido o no sustituido alquinil, sustituido o no sustituido cicloalquil, sustituido o no sustituido cicloalquilalquil, sustituido o no sustituido cicloalquenil, sustituido o no sustituido aril, sustituido o no sustituido arilalquil, sustituido o no sustituido heteroaril, sustituido o no sustituido heteroarilalquil, sustituido o no sustituido anillo heterocíclico y sustituido o no sustituido heterociclilalquil; o cuando están anexadas directamente a un átomo comun, Rx y Ry junto al átomo al cual están anexadas pueden formar un anillo cíclico opcionalmente sustituido de 3 a 7 miembros saturado, no saturado o parcialmente saturado, que puede incluir opcionalmente al menos dos heteroátomos seleccionados de O, NRa o S; cada ocurrencia de Ra es independientemente hidrogeno o sustituido o no sustituido alquil; R3 y R4 son independientemente seleccionados de hidrogeno, hidroxilo, halogeno, sustituido o no sustituido alquil, sustituido o no sustituido alquenil, sustituido o no sustituido alquinil, sustituido o no sustituido cicloalquil, sustituido o no sustituido cicloalquilalquil, sustituido o no sustituido cicloalquenil, sustituido o no sustituido aril, sustituido o no sustituido arilalquil, sustituido o no sustituido heteroaril, sustituido o no sustituido heteroarilalquil, sustituido o no sustituido anillo heterocíclico y sustituido o no sustituido heterociclilalquil; o R3 y R4 pueden combinarse para formar un anillo cíclico opcionalmente sustituido de 3 a 7 miembros saturado, o no saturado que puede incluir opcionalmente al menos un heteroátomo seleccionado de O, NRa, S, C(O) y S(O)0-2; y R5 es seleccionado de hidrogeno, hidroxilo, sustituido o no sustituido alquil, sustituido o no sustituido alquenil, sustituido o no sustituido alquinil, (CRxRy)nORx, CORx, COORx, CONRxRy, SO0-2NRxRy, NRxRy, NRx(CRxRy)nORx, NRx(CRxRy)nCN, (CH2)nNRxRy, (CH2)nCHRxRy, (CRxRy)NRxRy, NRx(CRxRy)nCONRxRy, (CH2)nNHCORx y (CH2)nNH(CH2)nSO2Rx, y (CH2)nNHSO2Rx; cada ocurrencia de R6 es independientemente seleccionada de hidrogeno, ciano, nitro, -NRxRy, halogeno, hidroxilo, sustituido o no sustituido alquil, sustituido o no sustituido alquenil, sustituido o no sustituido alquinil, sustituido o no sustituido cicloalquil, sustituido o no sustituido cicloalquilalquil, sustituido o no sustituido cicloalquenil, haloalquil, haloalcoxi, cicloalquilalcoxi, sustituido o no sustituido aril, sustituido o no sustituido arilalquil, sustituido o no sustituido heteroaril, sustituido o no sustituido heteroarilalquil, sustituido o no sustituido anillo heterocíclico y sustituido o no sustituido heterociclilalquil, -C(O)ORx, -ORx, -C(O)NRxRy, -C(O)Rx, y SO2NRxRy; cada ocurrencia de ônö es seleccionada de 0 a 5. Reivindicacion 14: Un compuesto de formula (2) o sus ésteres, tautomeros, estereoisomeros, o sus sales farmacéuticamente aceptables, donde, a cada ocurrencia, R1 y R2 son independientemente seleccionados de hidrogeno, hidroxilo, sustituido o no sustituido alquil, sustituido o no sustituido alquenil, sustituido o no sustituido alquinil, sustituido o no sustituido cicloalquil, sustituido o no sustituido cicloalquilalquil, (CRxRy)nORx, CORx, COORx, CONRxRy, SO2NRxRy, NRxRy, NRx(CRxRy)nORx, NRx(CRxRy)nCN, (CH2)nNRxRy, (CH2)nCHRxRy, (CRxRy)NRxRy, NRx(CRxRy)nCONRxRy, (CH2)nNHCORx y (CH2)nNH(CH2)nSO2Rx, y (CH2)nNHSO2Rx; cada ocurrencia de ônö es seleccionada de 0 a 5; R6a, R6b son independientemente seleccionadas de hidrogeno, ciano, nitro, -NRxRy, halogeno, hidroxilo, haloalquil, haloalcoxi, cicloalquilalcoxi, sustituidos o no sustituidos alquil, sustituidos o no sustituidos alquenil, sustituidos o no sustituidos alquinil, sustituidos o no sustituidos cicloalquil, sustituidos o no sustituidos cicloalquilalquil, sustituidos o no sustituidos cicloalquenil, sustituidos o no sustituidos aril, sustituidos o no sustituidos arilalquil, sustituidos o no sustituidos heteroaril, sustituidos o no sustituidos heteroarilalquil, sustituidos o no sustituidos anillos heterocíclicos y sustituidos o no sustituidos heterociclilalquil, -C(O)ORx, -ORx, -C(O)NRxRy, -C(O)Rx, -SO2Rx, -SO2NRxRy; R6a y R6b junto con el carbono al cual se unen, pueden formar un opcionalmente sustituido sistema de anillos de 4 a 14 miembros saturado, insaturado, o parcialmente saturado, que puede incluir opcionalmente uno o más heteroátomos seleccionados de O, N o S; Rx y Ry independientemente seleccionados de hidrogeno, hidroxilo, halogeno, sustituido o no sustituido alquil, sustituido o no sustituido alquenil, sustituido o no sustituido alquinil, sustituido o no sustituido cicloalquil, sustituido o no sustituido cicloalquilalquil, sustituido o no sustituido cicloalquenil, sustituido o no sustituido aril, sustituido o no sustituido arilalquil, sustituido o no sustituido heteroaril, sustituido o no sustituido heteroarilalquil, sustituido o no sustituido anillo heterocíclico y sustituido o no sustituido heterociclilalquil; o cuando están anexadas directamente a un átomo comun, Rx y Ry junto al átomo al cual están anexadas pueden formar un anillo cíclico opcionalmente sustituido de 3 a 7 miembros, saturado, insaturado o parcialmente saturado que puede opcionalmente incluir uno o más heteroátomos seleccionados de O, NRa o S; cada ocurrencia de Ra es hidrogeno o sustituido o no sustituido alqui
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1275MU2008 | 2008-06-17 | ||
| US8112008P | 2008-07-16 | 2008-07-16 | |
| IN1666MU2008 | 2008-08-05 | ||
| US9259208P | 2008-08-28 | 2008-08-28 | |
| IN1906MU2008 | 2008-09-09 | ||
| US9996108P | 2008-09-25 | 2008-09-25 | |
| IN2358MU2008 | 2008-11-05 | ||
| US11944608P | 2008-12-03 | 2008-12-03 | |
| IN156MU2009 | 2009-01-23 | ||
| US15023409P | 2009-02-05 | 2009-02-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR081045A1 true AR081045A1 (es) | 2012-06-06 |
Family
ID=41448215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090102199A AR081045A1 (es) | 2008-06-17 | 2009-06-17 | Derivados de quinazolinediona como moduladores trpa1 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US7951814B2 (es) |
| AR (1) | AR081045A1 (es) |
| TW (1) | TW201002703A (es) |
| WO (1) | WO2010004390A1 (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2411395T3 (pl) | 2009-03-23 | 2013-10-31 | Glenmark Pharmaceuticals Sa | Pochodne furopirymidynodionu jako modulatory TRPA1 |
| WO2010125469A1 (en) * | 2009-04-29 | 2010-11-04 | Glenmark Pharmaceuticals, S.A. | Pyrimidinedione-fused heterocyclic compounds as trpa1 modulators |
| WO2011114184A1 (en) * | 2010-03-15 | 2011-09-22 | Glenmark Pharmaceuticals S.A. | Amides of heterocyclic compounds as trpa1 inhibitors |
| WO2011132017A1 (en) * | 2010-04-19 | 2011-10-27 | Glenmark Pharmaceuticals S.A. | Pyrido[3,4-d]pyrimidinyl acetamide derivatives as trpa1 modulators |
| AU2011270701B2 (en) * | 2010-06-24 | 2015-05-14 | Alkermes Pharma Ireland Limited | Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
| JP5847827B2 (ja) | 2010-10-12 | 2016-01-27 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | Ｔｒｐａ１受容体アンタゴニスト |
| MY159059A (en) | 2010-12-20 | 2016-12-15 | Glenmark Pharmaceuticals Sa | 2-amino-4-arylthiazole compounds as trpa1 antagonists |
| WO2012098281A2 (es) | 2011-01-19 | 2012-07-26 | Universidad Miguel Hernández De Elche | Péptidos moduladores de receptores trp y sus usos |
| EP2520566A1 (en) | 2011-05-06 | 2012-11-07 | Orion Corporation | New Pharmaceutical Compounds |
| MX2013014679A (es) | 2011-06-13 | 2014-07-14 | Glenmark Pharmaceuticals Sa | Tratamiento de trastornos respiratorios usando antagonistas de trpa1. |
| WO2012176143A1 (en) | 2011-06-22 | 2012-12-27 | Glenmark Pharmaceuticals Sa | Pharmaceutical composition comprising a trpa1 antagonist and a beta-2 agonist |
| WO2012176105A1 (en) | 2011-06-22 | 2012-12-27 | Glenmark Pharmaceuticals Sa | Pharmaceutical composition comprising a trpa1 antagonist and a leukotriene receptor antagonist |
| WO2013014597A1 (en) | 2011-07-25 | 2013-01-31 | Glenmark Pharmaceuticals Sa | Pharmaceutical composition comprising a trpa1 antagonist and a steroid |
| CA2843965A1 (en) | 2011-08-09 | 2013-02-14 | Hydra Biosciences, Inc. | Inhibiting transient receptor potential ion channel trpa1 |
| US20140364445A1 (en) | 2011-12-05 | 2014-12-11 | Glenmark Pharmaceuticals S.A. | Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent |
| IN2014MN02467A (es) | 2012-06-08 | 2015-07-10 | Glenmark Pharmaceuticals Sa | |
| CN104822653B (zh) | 2012-10-01 | 2017-03-08 | 奥赖恩公司 | N‑丙‑2‑炔基甲酰胺衍生物及其作为trpa1拮抗剂的用途 |
| US9394308B2 (en) | 2013-01-18 | 2016-07-19 | Merck Sharp & Dohme Corp. | Inhibiting the transient receptor potential A1 ion channel |
| MX2016004741A (es) | 2013-10-15 | 2016-07-26 | Glenmark Pharmaceuticals Sa | Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico. |
| GB201401886D0 (en) | 2014-02-04 | 2014-03-19 | Lytix Biopharma As | Neurodegenerative therapies |
| TR201816624T4 (tr) | 2014-06-03 | 2018-11-21 | Idorsia Pharmaceuticals Ltd | Pirazol bileşikleri ve t tipi kalsiyum kanalı bloke edicileri olarak kullanımları. |
| WO2016042501A1 (en) | 2014-09-16 | 2016-03-24 | Glenmark Pharmaceuticals S.A. | Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain |
| WO2017060488A1 (en) | 2015-10-09 | 2017-04-13 | Almirall, S.A. | New trpa1 antagonists |
| WO2017064068A1 (en) | 2015-10-14 | 2017-04-20 | Almirall, S.A. | New trpa1 antagonists |
| BR112019011208A2 (pt) | 2016-12-16 | 2019-10-15 | Idorsia Pharmaceuticals Ltd | combinação farmacêutica, composição farmacêutica, e, kit de partes. |
| CN110234622B (zh) | 2017-02-06 | 2023-07-04 | 爱杜西亚药品有限公司 | 用于合成1-芳基-1-三氟甲基环丙烷的新颖方法 |
| CN110078747B (zh) * | 2019-04-11 | 2020-04-10 | 河南科技大学第一附属医院 | 一种用于医院消毒的新型噻唑类药物分子及其制备方法 |
| CN114671875A (zh) * | 2022-04-27 | 2022-06-28 | 成都施贝康生物医药科技有限公司 | 新型二氢嘧啶类化合物、异构体或盐及其制备方法和用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7465581B2 (en) | 2002-12-18 | 2008-12-16 | The Scripps Research Institute | ANKTM1, a cold-activated TRP-like channel expressed in nociceptive neurons |
| WO2005089206A2 (en) | 2004-03-13 | 2005-09-29 | Irm Llc | Modulators of ion channel trpa1 |
| TWI423819B (zh) * | 2005-12-22 | 2014-01-21 | Hydra Biosciences Inc | 用於調節ｔｒｐａ１功能之化合物 |
| AR065081A1 (es) | 2007-01-29 | 2009-05-13 | Xenon Pharmaceuticals Inc | Compuestos de quinazolinona y pirimidona fusionados y composicion farmaceutica |
| CN104825457B (zh) | 2007-06-22 | 2019-11-19 | 伊莱利利公司 | 用于治疗病症的方法和组合物 |
| EP2249820A1 (en) * | 2008-01-04 | 2010-11-17 | Abbott Laboratories | Trpa1 antagonists |
-
2009
- 2009-06-16 WO PCT/IB2009/005954 patent/WO2010004390A1/en active Application Filing
- 2009-06-16 US US12/485,600 patent/US7951814B2/en not_active Expired - Fee Related
- 2009-06-17 AR ARP090102199A patent/AR081045A1/es unknown
- 2009-06-17 TW TW098120299A patent/TW201002703A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010004390A1 (en) | 2010-01-14 |
| TW201002703A (en) | 2010-01-16 |
| US7951814B2 (en) | 2011-05-31 |
| US20090325987A1 (en) | 2009-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR081045A1 (es) | Derivados de quinazolinediona como moduladores trpa1 | |
| UY37795A (es) | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 | |
| AR059895A1 (es) | Derivados biciclicos de acidos carboxilicos que resultan de utilidad para tratar trastornos metabolicos | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| AR076754A1 (es) | Dihidropirimidinas y proceso de obtencion de las mismas | |
| AR079327A1 (es) | Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida | |
| PE20200388A1 (es) | Amidas heterociclicas de 5 miembros y biciclicas como inhibidores de rock | |
| AR076765A1 (es) | Compuestos antivirales | |
| AR079334A1 (es) | Derivados de oxazin amino | |
| AR075517A1 (es) | Derivados de isoxazol-isoxazol y de isoxazol-isotiazol | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| PE20181144A1 (es) | Derivados de heteroarilo como inhibidores de parp | |
| CO6150158A2 (es) | Piperidinas sustituidas que aumentan la actividad de p53 y su uso | |
| AR081587A1 (es) | DERIVADOS DE 5,6-DIHIDRO-2H-[1,4]OXAZIN-3-IL-AMINA UTILES COMO INHIBIDORES DE LA b-SECRETASA (BACE) | |
| BR112016016844A2 (pt) | Compostos heterocíclicos | |
| AR082499A1 (es) | Compuestos utiles para trastornos del sistema nervioso, inflamatorios, estomacales y como analgesicos | |
| BR112015028452A2 (pt) | agonistas do receptor somastatina subtipo 4 (sstr4) | |
| BR112015015275A2 (pt) | composto heterocíclico substituído por halogênio | |
| ECSP099461A (es) | Compuesto heteromonocíclico y uso del mismo | |
| EA201070864A1 (ru) | Новые гетероциклические соединения | |
| BR112013007566A2 (pt) | novos compostos bicíclicos | |
| BR112016019462B8 (pt) | Compostos heterocïclicos tricïclicos como inibidores de fosfoinosotida 3-cinase | |
| AR068376A1 (es) | Amidas heterociclicas utiles para inhibir la via hedgehog. | |
| EA202192900A1 (ru) | Модуляторы пути интегрированной реакции на стресс | |
| AR076830A1 (es) | Compuestos de carboxamidas de imidazol como moduladores de trpv3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |